Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Prehistoric wolf’s gut frozen in time reveals an ice age giant - 2Sweet Taste? Candy Fulfills You
- 3Manual for Individual accounting Rudiments for Fledglings
- 4Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 5Geminid meteor shower, one of the year's most reliable, peaks this weekend
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Tributes pour in for James Ransone, 'The Wire' actor who died at 46
- The Benefits of Rehearsing Careful Nurturing
- NASA troubleshoots Artemis II toilet problem in otherwise smooth flight
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Allow Innovative Progressions To have a Tremendous Effect
- UK consumer confidence plunges amid escalating Iran conflict
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- Inflammatory Merz remarks on migrants' violence against women slammed
